Pharmaceutical, biotech, and medical device commercialization and launch expert.

Commercial Strategy & Marketing | Insights & Analytics | Market Access & Value Strategy
Commercial Assesment | Customer Engagement Strategy | Demand Estimation | Go-to-Market Strategy | Journey Mapping and Market Landscape | Market Access Strategy | Message Testing | Payer research | Product Launch | Segmentation and Positioning Research | Sharpening the Marketing Message
  • // States
  • Save

John Hosier is a strategic advisor to the life sciences industry drawing on more then 25 years of sales, marketing and managed markets experience in commercial healthcare organizations.  He has provided insights to small molecule & biotechnology companies across multiple therapeutic areas but has maintained a heavy concentration in oncology and specialty pharma.  He has led brand launch; corporate, franchise, and strategic brand planning; commercial integration; organizational design; and operational effectiveness from multiple perspectives (as the client, as the independent consultant, and as an agency lead).  John’s firm has recently architected the launch of an oncology business unit for an emerging pharmaceutical client; led development of the managed markets, trade, and distribution strategy for the launch of a 505(b)2 for an established organization; and provided commercial assessment and recommendation of various licensing and co-promote deals between organizations.  John is an active mentor with various biotech/health tech accelerators in the tri-state area; is a council member and advisor to numerous market research firms serving the financial industry; serves as an expert witness on commercial matters for pharma/biotech; and is an adjunct professor of pharmaceutical marketing with the Silberman School of Business, FDU.

Before launching his own consulting firm, John held leadership positions of increasing responsibility including sales, marketing, account management, state & federal policy, pricing/contracting, and commercial operations.  His roles have spanned across 11 therapeutic areas (including orphan and ultra-orphan disease states) and 40 marketed products (oral solid and injectable/IV formulations) with various organizations including: Zeneca, Pharmacia & Upjohn, Pfizer, Roche, and Eisai.